June 23, 2022
1 min watch
Source/Disclosures
Published by:
Source:
Healio Interviews
Disclosures:
Luo reports receiving honoraria from Physicians’ Education Resource and Targeted Oncology; receiving research support to her institution from Erasca; and receiving personal fees from Blueprint Medicines, Daiichi Sankyo and Erasca.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ASCO Annual Meeting.
“What was interesting was the patients were randomized to pembrolizumab (Keytruda, Merck) plus ramucirumab (Cyramza, Eli Lilly), which is a VGEF inhibitor, vs. standard-of-care chemotherapy,” Luo, thoracic medical oncologist and cancer researcher with Dana-Farber and Harvard Medical School, said.
Reference:
- Reckamp KL, et al. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Take Homes in Lung Cancer
